14 recruiting, 5 unknown, 3 active not recruiting, 1 completed. 9 Phase 2, 6 Not applicable, 4 Phase 3, 1 Phase 1.
Follow this condition Literature Review of Oligometastasis trials Research Report on Oligometastasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT) Simulation-free workflow, SBRT - Oligometastasis, Oligometastatic Disease | Phase 1 | Recruiting | Case Comprehensive Cancer Center | 15 | 2026-02-27 | 2026-09-29 |
| Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA SBRT - Bladder Cancer, Urothelial Carcinoma (UC) | Not applicable | Recruiting | Istituto Clinico Humanitas | 44 | 2026-02-16 | 2026-04-30 |
| SMC Radiation Oncology SABR Cohort for Oligometastasis Stereotactic body radiotherapy (SBRT) - Stereotactic Body Radiation Therapy (SBRT), Oligometastasis | Recruiting | Samsung Medical Center | 60 | 2025-05-01 | 2025-08-13 | |
| stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database Breast Cancer, Oligometastasis | Recruiting | Istituto Clinico Humanitas | 300 | 2025-02-25 | 2026-02-11 | |
| Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma Ablation, system therapy - Advanced Hepatocellular Carcinoma, Lung Cancer | Recruiting | Sun Yat-sen University | 470 | 2024-10-04 | 2024-12-03 | |
| Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial Stereotactic Ablative Radiotherapy, Best Practice - Oligometastasis, Lung Cancer | Phase 3 | Recruiting | Roswell Park Cancer Institute | 800 | 2024-09-18 | 2026-02-04 |
| Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma ablation of oligometastasis - Advanced Hepatocellular Carcinoma, Oligometastasis | Not applicable | Recruiting | Sun Yat-sen University | 60 | 2024-08-01 | 2024-08-13 |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study Radical prostatectomy, Prostate irradiation, Surgical metastasectomy - Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone | Not yet recruiting | Medical University of Vienna | 500 | 2024-05-31 | 2024-05-28 | |
| Metastasis-directed Therapy for Oligometastases of Breast Cancer Systemic therapy for 12 weeks after primary registration, Radiation therapy (SBRT/conventional RT), Surgery - Breast Cancer, Oligometastasis | Phase 3 | Recruiting | Tokyo Medical and Dental University | 146 | 2023-11-08 | 2026-10-07 |
| Metastasis-directed Therapy for Oligorecurrent Prostate Cancer Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 873 | 2022-04-20 | 2024-07-03 |
| Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC Toripalimab in Combination With Platinum-based Chemotherapy, Surgical treatment stage, Adjuvant treatment stage - NSCLC Stage IV, Oligometastasis | Phase 2 | Unknown | Tang-Du Hospital | 30 | 2021-08-31 | 2021-09-24 |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease - Prostate Cancer, Oligometastasis | Phase 2 / Phase 3 | Active not recruiting | VA Office of Research and Development | 378 | 2021-07-01 | 2026-10-19 |
| Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) Stereotactic body radiotherapy, Palliative RT - Gynecologic Cancer, Skin Cancer | Not applicable | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 200 | 2021-06-10 | 2024-08-26 |
| Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer Darolutamide, metastasis-directed treatment - Prostate Cancer, Prostate Cancer Recurrent | Phase 2 | Unknown | University Hospital, Ghent | 124 | 2021-02-12 | 2024-02-28 |
| Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis Microwave Ablation combination with chemotherapy - Pancreatic Cancer Metastatic to Liver, Oligometastasis | Phase 2 | Unknown | Fudan University | 50 | 2021-01-01 | 2020-12-21 |
| Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer Sintilimab - Oligometastasis, Lung Neoplasms | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 44 | 2020-09-01 | 2020-07-24 |
| Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis Radical resection, Radical radiotherapy, Palliative treatment - Breast Cancer, Oligometastasis | Not applicable | Recruiting | xuexin he | 183 | 2020-05-09 | 2020-05-12 |
| Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma Camrelizumab - Nasopharyngeal Carcinoma, Oligometastasis | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 52 | 2020-01-01 | 2023-06-18 |
| Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC Durvalumab, Carboplatin, Paclitaxel - Non-small Cell Lung Cancer, Stage IV | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 96 | 2019-11-19 | 2026-10-05 |
| Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry Oligometastasis, Metastatic Cancer | Recruiting | Duke University | 300 | 2019-09-26 | 2026-02-05 |
Showing 20 of 24. Sign in to see all of them.
Prostatic Neoplasms (8) · Breast Neoplasms (4) · Neoplasm Metastasis (4) · Esophageal Neoplasms (3) · Lung Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Head and Neck Neoplasms (2) · Stomach Neoplasms (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Transitional Cell (1) · Kidney Neoplasms (1) · Liver Neoplasms (1) · Lymphatic Metastasis (1)
Neoplasms (20) · Neoplasms by Site (19) · Male Urogenital Diseases (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Genital Diseases (8) · Genital Diseases, Male (8) · Genital Neoplasms, Male (8) · Prostatic Diseases (8) · Lung Diseases (5) · Neoplastic Processes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5)
Radiosurgery (5) · Radiotherapy (4) · Androgen Antagonists (2) · Drug Therapy (2) · Metastasectomy (2) · apalutamide (2) · darolutamide (2) · enzalutamide (2) · Abiraterone Acetate (1) · Capecitabine (1) · Carboplatin (1) · Docetaxel (1) · Fluorouracil (1) · Flutamide (1) · Gonadotropin-Releasing Hormone (1)
Istituto Clinico Humanitas (2) · Sun Yat-sen University (2) · Case Comprehensive Cancer Center (1) · Duke University (1) · ETOP IBCSG Partners Foundation (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fudan University (1) · Institut Cancerologie de l'Ouest (1) · M.D. Anderson Cancer Center (1) · Medical University of Vienna (1) · Nanfang Hospital, Southern Medical University (1) · Roswell Park Cancer Institute (1) · Samsung Medical Center (1) · Tang-Du Hospital (1) · Tianjin Medical University Second Hospital (1)
China (6) · United States (6) · Italy (4) · Belgium (3) · France (2) · Germany (2) · Switzerland (2) · Japan (1) · Netherlands (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Feng Duan, MD (2) · Abhishek Solanki, MD MS (1) · Alejandro Sanchez (1) · Anurag Singh, MD (1) · Fumitaka Hara, M.D.Ph.D. (1) · Ikuno Nishibuchi, M.D.Ph.D. (1) · Isabelle Schmitt-Opitz, MD (1) · Jian Guan, Ph.D. (1) · Joseph Salama, MD (1) · Lauren Henke, MD, MSCI (1) · Matthias Guckenberger (1) · Matthias Guckenberger, MD-PhD (1) · Naoto Shikama, M.D.Ph.D. (1) · Pawel G Rajwa, MD PhD (1)
PMID 36503429, PMID 38421252, PMID 38785484, PMID 39881423, PMID 41615067, PMID 42140755, PMID 42276876
2018 (1), I01CX002277 (1)